Ketek may lose two of three indications
An FDA advisory committee said Sanofi-Aventis’ Ketek should no longer be marketed for two of its three indications, bronchitis or ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.